Genzyme Beats Investor Suit Over Stock Plunge
A federal judge dismissed a consolidated class action Friday accusing Genzyme Corp. of misleading the U.S. Food and Drug Administration and selling its securities at artificially inflated prices, saying alleged misstatements...To view the full article, register now.
Already a subscriber? Click here to view full article